| Literature DB >> 36105983 |
Guowei Gu1, Tao Zhang1, Jianyuan Zhao1, Wuli Zhao1, Yan Tang1,2, Lu Wang1, Shan Cen1, Liyan Yu1, Dewu Zhang1.
Abstract
Three new chromanone dimer derivatives, paecilins F-H (1-3) and ten known compounds (4-13), were obtained from the mutant strains of Penicillium oxalicum 114-2. Their structures were elucidated by extensive analysis of spectroscopic data and comparison with reported data, and the configurations of 1-3 were resolved by quantum chemical calculations of NMR shifts and ECD spectra. Compounds 5 and 11 showed significant anti-influenza A virus activities with IC50 values of 5.6 and 6.9 μM, respectively. Compounds 8 and 9 displayed cytotoxic activities against the MIA-PaCa-2 cell line with IC50 values of 2.6 and 2.1 μM, respectively. Compound 10 exhibited antibacterial activities against Bacillus cereus with a MIC value of 4 μg mL-1. This journal is © The Royal Society of Chemistry.Entities:
Year: 2022 PMID: 36105983 PMCID: PMC9364356 DOI: 10.1039/d2ra02639b
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Structures of compounds 1–13.
1H (600 MHz) and 13C NMR (150 MHz) data of compounds 1–3
| No. | 1 | 2 | 3 | |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| 1 | 158.2, s | 159.3, s | 160.2, s | |||
| 2 | 117.0, s | 116.6, s | 109.5, d | 6.49, d (8.4) | ||
| 3 | 140.8, d | 7.49, d (8.4) | 141.7, d | 7.37, d (8.4) | 141.0, d | 7.75, d (8.4) |
| 4 | 107.2, d | 6.68, d (8.4) | 107.9, d | 6.67, d (8.4) | 114.0, s | |
| 4a | 158.3, s | 159.3, s | 155.4, s | |||
| 5 | 81.8, d | 4.94, d (6.6) | 82.7, d | 4.80, d (6.6) | 81.6, d | 4.85, d (6.6) |
| 6 | 32.6, d | 2.98, m | 33.7, d | 3.00, m | 32.8, d | 2.88, m |
| 7 | 36.7, t | 2.83, dd (17.4, 8.4), 2.33, dd (17.4, 6.0) | 36.8, t | 2.69, dd (17.4, 8.4), 2.50, dd (17.4, 8.4) | 35.8, t | 2.45, dd (16.8, 8.4), 1.72, dd (16.8, 9.0) |
| 8 | 175.5, s | 175.0, s | 174.9, s | |||
| 9 | 195.3, s | 194.2, s | 194.6, s | |||
| 9a | 107.1, s | 107.7, s | 107.3, s | |||
| 10 | 39.1, t | 3.61, d (17.4), 3.06, d (17.4) | 40.0, t | 3.27, d (17.4), 3.20, d (17.4) | 39.2, t | 3.56, d (18.0), 3.17, d (18.0) |
| 10a | 83.8, s | 84.7, s | 85.3, s | |||
| 11 | 14.7, q | 1.18, d (7.2) | 15.0, q | 1.36, d (7.2) | 14.3, q | 1.00, d (7.2) |
| 12 | 169.1, s | 169.1, s | 169.1, s | |||
| 13 | 53.6, q | 3.70, s | 53.7, q | 3.77, s | 53.6, q | 3.75, s |
| 1′ | 158.2, s | 159.6, s | 160.2, s | |||
| 2′ | 115.5, s | 117.6, s | 109.5, d | 6.49, d (8.4) | ||
| 3′ | 140.5, d | 7.47, d (8.4) | 151.5, s | 141.0, d | 7.75, d (8.4) | |
| 4′ | 107.2, d | 6.61, d (8.4) | 109.1, d | 6.57, s | 114.0, s | |
| 4a′ | 159.2, s | 158.9, s | 155.4, s | |||
| 5′ | 74.8, d | 3.89, d (5.4) | 81.1, d | 4.88, d (8.4, 6.0) | 81.6, d | 4.85, d (6.6) |
| 6′ | 30.8, d | 2.22, m | 22.2, t | 2.45, m | 32.8, d | 2.88, m |
| 7 | 39.8, t | 2.41, m, 2.19, m | 27.8, t | 2.72, m, 2.60, m | 35.8, t | 2.45, dd (16.8, 8.4), 1.72, dd (16.8, 9.0) |
| 8′ | 173.6, s | 175.7, s | 174.9, s | |||
| 9′ | 197.2, s | 193.2, s | 194.6, s | |||
| 9a′ | 106.9, s | 105.8, s | 107.3, s | |||
| 10′ | 40.3, t | 3.50, d (17.4), 3.01, d (17.4) | 39.6, t | 3.11, d (16.8), 2.97, d (16.8) | 39.2, t | 3.56, d (18.0), 3.17, d (18.0) |
| 10a′ | 87.7, s | 84.2, s | 85.3, s | |||
| 11′ | 13.9, q | 0.93, d (6.0) | 21.5, q | 2.12, s | 14.3, q | 1.00, d (7.2) |
| 12′ | 170.4, s | 169.1, s | 169.1, s | |||
| 13′ | 53.0, q | 3.64, s | 53.9, q | 3.79, s | 53.6, q | 3.75, s |
| 1-OH | 11.82, s | 11.74, s | 11.57, s | |||
| 1′-OH | 11.91, s | 11.73, s | 11.57, s | |||
| 5′-OH | 5.73, d, (6.6) | |||||
Recorded in DMSO-d6.
Recorded in CDCl3.
Fig. 2Key COSY, HMBC and NOESY correlations of 1–3.
Fig. 3The experimental ECD spectrum of 1, and the calculated ECD spectra of 1Aa–1Ac.
Fig. 4The experimental ECD spectrum of 3, and the calculated ECD spectra of 3Aa and 3Ab.
The anti-IAV activities of 1–13
| Compounds | Inhibition rate (%) in 10 μM | IC50 (μM) | CC50 (μM) | SI |
|---|---|---|---|---|
| 1 | 23.5 ± 1.0 | — | — | |
| 2 | 27.1 ± 3.1 | — | — | |
| 3 | 18.7 ± 6.1 | — | — | |
| 4 | 27.1 ± 4.6 | — | — | |
| 5 | 90.8 ± 2.1 | 5.6 ± 0.7 | 46.2 ± 2.0 | 8.3 |
| 6 | 16.4 ± 1.5 | — | — | |
| 7 | 74.7 ± 7.1 | — | 12.2 ± 1.2 | |
| 8 | 65.5 ± 3.1 | — | 10.5 ± 3.4 | |
| 9 | 49.6 ± 5.4 | — | 13.2 ± 2.5 | |
| 10 | 40.2 ± 7.4 | — | — | |
| 11 | 97.2 ± 1.8 | 6.9 ± 1.1 | >100 | >14.5 |
| 12 | 15.0 ± 4.8 | — | — | |
| 13 | 49.9 ± 1.0 | — | — | |
| Ribavirin | 90.3 ± 5.2 (50 μM) | 28.2 ± 4.4 | >100 | >3.5 |